BRAF and melanoma: Given these considerations, the National Comprehensive Cancer Network (NCCN) recommends combination therapy as a preferred regimen for treating unresectable BRAF V600E melanoma, underscoring the efficacy of these therapies while also acknowledging the potential for increased toxicity and the challenges associated with resistance [28].